Noriyoshi Ogawa

Noriyoshi Ogawa

Auto-generated profile, based on publicly available information

Noriyoshi Ogawa

Division of Immunology and Rheumatology, Department of Internal Medicine 3, Hamamatsu University School of Medicine, Hamamatsu, 431-3192, Japan

Research Focus & Metrics

Academic Career Length

22Years (2005-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
22 December 2005 in European Journal of Haematology
Verified
Journal Article
Closed access
PDF file
YHYuko Hirose
Yuko Hirose
MYMASAKI Yasufumi
MASAKI Yasufumi
TSToshioki Sawaki
Toshioki Sawaki
KSKumiko Shimoyama
Kumiko Shimoyama
HKHiromi Karasawa
Hiromi Karasawa
HUHisanori Umehara
Hisanori Umehara

1 January 2011 in Biological and Pharmaceutical Bulletin
Verified
Journal Article
Open access
PDF file
YMYasuaki Mino
Yasuaki Mino
TNTakafumi Naito
Takafumi Naito
KSKumiko Shimoyama
Kumiko Shimoyama
NONoriyoshi Ogawa
Noriyoshi Ogawa
JKJunichi Kawakami
Junichi Kawakami
The aim of this study was to identify factors affecting the pharmacokinetics of mycophenolic acid (MPA) and its 7-O-glucuronide (MPAG) in systemic lupus erythematosus (SLE) patients. Thirty-one SLE patients in remission maintenance phase treated with mycophenolate mofetil (median 1500 mg/d) and prednisolone and followed-up for up to 56 months (median 13 months) were enrolled. Creatinine clearance and metal medication were significant predictors accounting for interindividual variability in the dose-normalized predose plasma concentration (C0) of MPA (adjusted R2=0.305, p=0.01) in a multivariate analysis. Dose-normalized MPAG C0 was significantly correlated with only creatinine clearance (adjusted R2=0.135, p=0.03). The free fraction of MPA was significantly correlated with only serum albumin (adjusted R2=0.700, p<0.01). The free fraction of MPAG was significantly correlated with serum albumin, metal medication, and age (adjusted R2=0.598, p=0.02). In conclusion, renal function and co-administered metal influenced the pharmacokinetics of MPA and MPAG in SLE patients in remission maintenance phase.

24 February 2024 in Respiratory Medicine
Verified
Journal Article
Open access
NENoriyuki Enomoto
Noriyuki Enomoto
SYShusuke Yazawa
Shusuke Yazawa
YMYasutaka Mochizuka
Yasutaka Mochizuka
AFAtsuki Fukada
Atsuki Fukada
YTYuko Tanaka
Yuko Tanaka
TSTakafumi Suda
Takafumi Suda
Patients with idiopathic interstitial pneumonia (IIP) have a favourable prognosis when they have interstitial pneumonia with autoimmune features (IPAF). However, precise IPAF-related findings from high-resolution computed tomography (HRCT) and lung histopathological specimens and the treatment response have not been fully determined. Therefore, this study was conducted to evaluate the relationship between findings on HRCT or lung histopathological specimens and the progression of interstitial pneumonia in patients with IPAF. This multicentre cohort study prospectively enrolled consecutive patients with IIP. At the diagnosis of IIP, we systematically evaluated 74 features suggestive of connective tissue diseases and followed them up. HRCT, lung specimens, serum antibodies, and the clinical course were also evaluated. Among 222 patients with IIP, 26 (11.7%) fulfilled the IPAF criteria. During a median observation period of 36 months, patients with IPAF showed better survival than those without IPAF (p = 0.034). While histopathological findings were not related to IPAF, nonspecific interstitial pneumonia (NSIP) with organizing pneumonia (OP) overlap was the most prevalent HRCT pattern (p < 0.001) and the consolidation opacity was the most common radiological finding in IPAF (p = 0.017). Furthermore, in patients with IPAF, the diagnosis of COP or NSIP with OP overlap was associated with a higher increase in %FVC in 1 year than in those with idiopathic pulmonary fibrosis, NSIP, or unclassifiable IIP (p = 0.002). This study shows the presence of consolidation opacity on HRCT and the diagnosis of COP or NSIP with OP overlap are associated with IPAF and its favourable treatment response in patients with IPAF.

17 December 2024 in Respiratory Investigation
Verified
Journal Article
Closed access
HNHiromasa Nakayasu
Hiromasa Nakayasu
MKMasato Karayama
Masato Karayama
NENoriyuki Enomoto
Noriyuki Enomoto
YIYusuke Inoue
Yusuke Inoue
HYHideki Yasui
Hideki Yasui
TSTakafumi Suda
Takafumi Suda

31 January 2025 in Respiratory Investigation
Verified
Journal Article
Closed access
MKMasato Kono
Masato Kono
NENoriyuki Enomoto
Noriyuki Enomoto
YIYusuke Inoue
Yusuke Inoue
HYHideki Yasui
Hideki Yasui
MKMasato Karayama
Masato Karayama
TSTakafumi Suda
Takafumi Suda